Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026
- Participants achieving HBsAg loss with pegylated interferon alfa (PEG-IFNα) ± elebsiran or BRII-179 demonstrated favorable off-treatment clinical outcomes, with most HBsAg rebounds <10 IU/mL and HBV DNA rebound infrequent and not associated...
Berlin Heals Presents Positive Late Breaking Results from the CMIC-III First-In-Human Less Invasive Study
High Impact Session presented at Heart Rhythm Society's Congress in Chicago First time showing results of new Less Invasive approach Improvement in Left Ventricular Ejection Fraction (LVEF), 6 Minute Walk Test (6MWT), Quality of Life (QOL) and New...
Kia Presents Vision Meta Turismo at Milan Design Week, Redefining the Grand Tourer for the Digital Age
Vision Meta Turismo concept embodies Kia's futuristic approach to a new era of electric mobility, offering a more dynamic, engaging, and visceral driving experience Contemporary reinterpretation of three core experiences: performance driving,...
Ractigen Therapeutics Presents Positive Phase I Data for RAG-17 in SOD1-ALS at the 2026 AAN Annual Meeting, Demonstrating 81% Reduction in Neurofilament Light Chain
— Single intrathecal dose of SCAD-siRNA therapeutic RAG-17 yields favorable safety profile and profound, durable biomarker reductions — — Preliminary data from 180 mg cohort shows trends of clinical stabilization (ALSFRS-R) — — Phase II trial is now...
AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL
SAN DIEGO, April 20, 2026 /PRNewswire/ -- Abogen, a clinical-stage biotechnology company focused on RNA innovation, today announced preliminary clinical results from the first-in-human (FIH) study of ABO2203 in patients with relapsed/refractory...
Immunofoco Presents Preclinical Data for IMV102, an In Vivo CAR-T Candidate, Demonstrating Durable Tumor Control at the AACR 2026
SHANGHAI, April 20, 2026 /PRNewswire/ -- Immunofoco today announced the presentation of new preclinical data for its in vivo BCMA-targeting CAR-T candidate, IMV102, at the AACR Annual Meeting 2026. The data demonstrate that IMV102 achieved potent...
Fapon Biopharma Presents at AACR Annual Meeting 2026, Showcasing Core Technology Platforms and Advancing Pipeline
SAN DIEGO, April 20, 2026 /PRNewswire/ -- Fapon Biopharma, a clinical-stage biotech company innovating therapeutic antibodies and fusion proteins, is pleased to announce its participation in the AACR Annual Meeting 2026, taking place April 19–22,...
Antengene Presents Three Novel Programs at AACR 2026, Highlighting Next-Generation ADC and AnTenGager® TCEs
SHANGHAI and HONG KONG, April 18, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class...
Phrontline Biopharma Presents Preclinical Data for TJ106, a Biparatopic HER2 Dual-Payload ADC, at American Association for Cancer Research Annual Meeting 2026
Data Demonstrate Activity in HER2-Low and ADC-Resistant Tumor Models, Supporting Advancement Toward IND SHANGHAI and SUZHOU, China, April 14, 2026 /PRNewswire/ -- Phrontline Biopharma today announced the presentation of preclinical data for TJ106, a...
NEC Philippines Presents Advanced Aviation Portfolio at the 8th Philippine Airport Summit 2026
MANILA, Philippines, April 13, 2026 /PRNewswire/ -- NEC Philippines today announced its inaugural participation in the 8th Philippine Airport Summit 2026, to be held on April 22–23 at the City of Dreams, Manila. The move marks the official entry of...